Literature DB >> 27650362

A phase II study of vascular endothelial growth factor trap (Aflibercept, NSC 724770) in patients with myelodysplastic syndrome: a California Cancer Consortium Study.

Mark H Kirschbaum1, Paul Frankel2, Timothy W Synold3, Jasmine Zain1, David Claxton4, Joseph Tuscano5, Edward M Newman3, David R Gandara5, Primo N Lara5.   

Abstract

Entities:  

Keywords:  clinical trials; myelodysplastic syndrome; vascular endothelial growth factor

Mesh：

Substances：

Year:  2016        PMID： 27650362      PMCID： PMC5360527          DOI： 10.1111/bjh.14333

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  9 in total

1.  The anti-angiogenesis agent, AG-013736, has minimal activity in elderly patients with poor prognosis acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).

Authors:  Francis J Giles; William T Bellamy; Zeev Estrov; Susan M O'Brien; Srdan Verstovsek; Farhad Ravandi; Miloslav Beran; Paul Bycott; Yazdi Pithavala; Heidi Steinfeldt; Steven D Reich; Alan F List; Karen W L Yee
Journal:  Leuk Res       Date:  2005-12-05       Impact factor: 3.156

2.  Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia.

Authors:  W Fiedler; U Graeven; S Ergün; S Verago; N Kilic; M Stockschläder; D K Hossfeld
Journal:  Blood       Date:  1997-03-15       Impact factor: 22.113

3.  Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes.

Authors:  W T Bellamy; L Richter; D Sirjani; C Roxas; B Glinsmann-Gibson; Y Frutiger; T M Grogan; A F List
Journal:  Blood       Date:  2001-03-01       Impact factor: 22.113

4.  Treatment of myelodysplastic syndromes with excess of blasts by bevacizumab is well tolerated and is associated with a decrease of VEGF plasma level.

Authors:  Laurence Legros; Bohrane Slama; Jean-Michel Karsenti; Norbert Vey; Shanti Natarajan-Amé; Eric Watel; Bruno Richard; Krimo Bouabdallah; Lionel Mannone; Maxime Benchetrit; Irit Touitou; Sébastien Huault; Jérome Durivault; Damien Ambroseti; Anne-Odile Hueber; Pierre Fenaux; Francois Dreyfus
Journal:  Ann Hematol       Date:  2011-05-07       Impact factor: 3.673

5.  Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia.

Authors:  Bruce D Cheson; Peter L Greenberg; John M Bennett; Bob Lowenberg; Pierre W Wijermans; Stephen D Nimer; Antonio Pinto; Miloslav Beran; Theo M de Witte; Richard M Stone; Moshe Mittelman; Guillermo F Sanz; Steven D Gore; Charles A Schiffer; Hagop Kantarjian
Journal:  Blood       Date:  2006-04-11       Impact factor: 22.113

6.  Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors.

Authors:  A Craig Lockhart; Mace L Rothenberg; Jakob Dupont; Wendy Cooper; Paul Chevalier; Lars Sternas; Giliane Buzenet; Elizabeth Koehler; Jeffrey A Sosman; Lawrence H Schwartz; David H Gultekin; Jason A Koutcher; Edwin F Donnelly; Ric Andal; Isabelle Dancy; David R Spriggs; William P Tew
Journal:  J Clin Oncol       Date:  2009-11-30       Impact factor: 44.544

7.  A phase II study of the oral VEGF receptor tyrosine kinase inhibitor vatalanib (PTK787/ZK222584) in myelodysplastic syndrome: Cancer and Leukemia Group B study 10105 (Alliance).

Authors:  Pankaj Gupta; Flora Mulkey; Robert P Hasserjian; Ben L Sanford; Ravi Vij; David D Hurd; Olatoyosi M Odenike; Clara D Bloomfield; Kouros Owzar; Richard M Stone; Richard A Larson
Journal:  Invest New Drugs       Date:  2013-05-23       Impact factor: 3.850

8.  Bone marrow histology in myelodysplastic syndromes. I. Histological findings in myelodysplastic syndromes and comparison with bone marrow smears.

Authors:  G Tricot; C De Wolf-Peeters; B Hendrickx; R L Verwilghen
Journal:  Br J Haematol       Date:  1984-07       Impact factor: 6.998

9.  VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism.

Authors:  Hans-Peter Gerber; Ajay K Malik; Gregg P Solar; Daniel Sherman; Xiao Huan Liang; Gloria Meng; Kyu Hong; James C Marsters; Napoleone Ferrara
Journal:  Nature       Date:  2002-06-27       Impact factor: 49.962
  9 in total
  1 in total

1.  A nonrandomized phase I and biomarker trial of regorafenib in advanced myeloid malignancies.

Authors:  Joan How; Siyang Ren; Jennifer Lombardi-Story; Meghan Bergeron; Julia Foster; Phillip C Amrein; Andrew M Brunner; Amir T Fathi; Hanno Hock; Anna Khachatryan; Hiroto Kikuchi; Mei Rosa Ng; Jenna Moran; Rupa Narayan; Donna Neuberg; Aura Ramos; Tina Som; Meghan Vartanian; Yi-Bin Chen; Dan G Duda; Gabriela S Hobbs
Journal:  EJHaem       Date:  2022-03-06
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.